Your Best Treatment Shouldn't Lose to the Easiest-to-Reimburse One.
Payer coverage gaps, step therapy barriers, and prior auth friction suppress prescriber adoption. We map the obstacles and eliminate them.
Payer Coverage Intelligence
DAXXIFY (J0589) Coverage by Payer
Real-world coverage, step therapy, and authorization requirements across major payers. Friction Score measures total reimbursement friction (75+ = critical barriers).
| Payer | Covered | PA Required | Step Therapy | Max Dose | Auth Duration | Friction |
|---|---|---|---|---|---|---|
| UnitedHealthcare | Yes | Yes | Botox-first | 300 units/84 days | 6 months | 85 |
| Anthem | Yes | Yes | Any prior botulinum toxin | 300 units | 12 months | 75 |
| Aetna | Yes | Yes | Any prior botulinum toxin | 250 units | 6 months | 72 |
| Cigna | Yes | Yes | Botox-first (strict) | 300 units | 6 months | 80 |
| Humana | Yes | Yes | Flexible | 300 units | 12 months | 65 |
| BCBS-TX | Yes | Yes | Varies by plan | 250 units | 6 months | 70 |
| Medicare (FFS) | Yes | No | None | Per LCD | Continuous | 60 |
| TRICARE | Yes | Yes | Flexible | 300 units | 12 months | 55 |
Adoption Economics
The Adoption Gap: When Reimbursement Friction Suppresses Prescribing
Providers in high-friction markets prescribe novel therapies 30-40% less frequently.
High-Friction Market
Prior Auth Required
7-10 days per submission
Step Therapy Barriers
Must fail 2+ generics first
Denial Rate
22-28% on first submission
Prescriber Behavior
Default to Botox
Even when clinical evidence favors your drug, prescribers choose the path of least resistance.
Low-Friction Market
Prior Auth Streamlined
2-3 days, 95% approval rate
No Step Therapy
Direct coverage with clinical justification
Denial Rate
4-6% on first submission
Prescriber Behavior
Adopt based on evidence
Your drug gets tried. Clinical outcomes drive future prescribing.
For Every 5% Reduction in Denial Rate
Prescriber adoption increases an estimated 12-15%.
Removing reimbursement friction isn't a compliance issue. It's a market share issue. In high-friction markets, your best-in-class treatment loses to ease of prescribing. We eliminate that friction barrier.
Step Therapy & Prior Authorization
Step Therapy Requirements by Payer
What must be tried first, documentation requirements, bypass strategies, and state law exceptions.
First-Line Required
Botox (botulinum toxin type A)
Documentation Required
Failed trial 4+ weeks, clinical notes, imaging
Bypass Strategies
Documented ADR, allergy, contraindication
Exception Criteria
IgE-mediated allergy or prior severe reaction
State Step Therapy Exception Laws
California
AB 347 (Cal. Insurance Code § 10123.197)
Step therapy exception timeline (30 days max) — Source: California Assembly Bill 347, effective 2021, Insurance Code § 10123.197
Massachusetts
Ch 208
Step therapy exceptions for antineoplastic agents
Virginia
HB 2044
Step therapy exception process
Illinois
SB 1564
Prior authorization transparency
New York
Ch 512
Step therapy exception procedures
Documentation Intelligence
Pre-Submission Documentation Checklist
Missing documentation is the #1 cause of denials. Know what each payer requires before you submit.
| Documentation Item | Required by Payer(s) | Impact if Missing | Pro Tip |
|---|---|---|---|
Neurologist Evaluation | UHC, Cigna, Aetna, Anthem | +18% denial probability | Must be within 6 months. Specialist credentials required for payer review. |
TWSTRS Score ≥20 | Cigna, UHC (selective) | +25% denial probability | Toronto Western Spasmodic Torticollis Rating Scale. Document baseline and severity. |
Prior Medication History | All payers | +12% denial probability | List all prior oral and injectable treatments with dates and outcomes. |
Prior Botulinum Toxin History | All payers (step therapy) | +35% denial probability (step therapy bypass) | Product type, dose, injection date, duration of effect. Critical for step therapy exception. |
Muscle Selection Rationale | UHC, Aetna, Cigna | +8% denial probability | Explain which muscles you are targeting and why. Include clinical reasoning. |
EMG Guidance Documentation | Selective (academic centers) | +5% denial probability | If performed, include EMG results. Shows procedural precision. |
Prior PA Number | All payers | +22% denial probability | If prior approval exists, include PA number. Expedites current request. |
J0589 (DAXXIFY) Correct Coding | All payers | +30% denial probability (coding) | Verify CPT, units, frequency. Coding error = automatic denial for unbundling. |
Missing Documentation = Automatic Denial
Most denials aren't about medical necessity. They're about missing or incomplete documentation. A single missing item can trigger a denial that reverses on appeal—but appeals cost time and resources.
Get it right the first time. Use this checklist before every submission.
Buy-and-Bill Economics
Buy-and-Bill Financial Risk by Payer
Buy-and-bill denials create immediate cash flow risk. Understanding payer-specific denial rates is critical for financial planning.
UnitedHealthcare
$330
Risk per denied claim
Denial Rate: 22%
Cigna
$300
Risk per denied claim
Denial Rate: 20%
Aetna
$285
Risk per denied claim
Denial Rate: 19%
Anthem
$270
Risk per denied claim
Denial Rate: 18%
BCBS-TX
$255
Risk per denied claim
Denial Rate: 17%
Humana
$225
Risk per denied claim
Denial Rate: 15%
Medicare (FFS)
$120
Risk per denied claim
Denial Rate: 8%
TRICARE
$180
Risk per denied claim
Denial Rate: 12%
The Cash Flow Problem
At ~$1,500 per vial and a 22% denial rate (UnitedHealthcare average), practices risk $330 per denied claim. That's immediate out-of-pocket expense before appeal review.
High-Risk Payer (UHC)
$330
per denied vial
10 Denied Claims/Month
$3,300
monthly cash flow impact
Annual Impact
$39,600
before appeals recovery
Why Providers Default to Established Products
Buy-and-bill risk is the #1 reason providers prescribe Botox instead of your drug. It's not clinical preference—it's financial risk management. Reduce payer friction, reduce financial risk, and your adoption numbers improve.
Ready to Remove Reimbursement Friction?
Get a custom reimbursement friction analysis for your drug. We'll map payer-specific barriers, identify prescriber adoption obstacles, and show you the path to market penetration.
Contact Information
ned@coverageunlocked.com